Hanley Jr. Michael Conick Insider Trades

Insider Trading History

Track insider trading activity for Hanley Jr. Michael Conick. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Alto Neuroscience
Alto Neuroscience ANRO
CHIEF OPERATING OFFICER
Holding Value $2.62M 131,000 shares
Last Trade
Feb 11, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.19M 131,000 shares
$16.71
$20.03
Alto Neuroscience
Alto Neuroscience ANRO
CHIEF OPERATING OFFICER
Holding Value $3.77M 188,000 shares
Last Trade
Jul 03, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$754k 321,000 shares
$2.35
$20.03
Alto Neuroscience
Alto Neuroscience ANRO
CHIEF OPERATING OFFICER
Holding Value $0 0 shares
Last Trade
Jul 03, 2025 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$754k 321,000 shares
$2.35
$20.03
Alto Neuroscience
Alto Neuroscience ANRO
CHIEF OPERATING OFFICER
Holding Value $2.5M 125,000 shares
Last Trade
Feb 05, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$525k 125,000 shares
$4.20
$20.03
Spyre Therapeutics
Spyre Therapeutics SYRE
Chief Business Officer
Holding Value $39.2M 500,000 shares
Last Trade
Feb 23, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$78.48
Aeglea BioTherapeutics
Aeglea BioTherapeutics AGLE
Chief Business Officer
Holding Value $6.01M 500,000 shares
Last Trade
Feb 23, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$5.5M 500,000 shares
$11.00
$12.01
Aeglea BioTherapeutics
Aeglea BioTherapeutics AGLE
Chief Business Officer
Holding Value $1.56M 130,000 shares
Last Trade
Aug 23, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$4.42M 260,000 shares
$17.00
$12.01
Spyre Therapeutics
Spyre Therapeutics SYRE
Chief Business Officer
Holding Value $10.2M 130,000 shares
Last Trade
Aug 23, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$78.48
Spyre Therapeutics
Spyre Therapeutics SYRE
Chief Commercial Officer
Holding Value $2.84M 36,200 shares
Last Trade
Jun 08, 2022 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
No data
No data
$78.48
Aeglea BioTherapeutics
Aeglea BioTherapeutics AGLE
Chief Commercial Officer
Holding Value $435k 36,200 shares
Last Trade
Jun 08, 2022 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$494k 28,200 shares
$17.51
$12.01
Aeglea BioTherapeutics
Aeglea BioTherapeutics AGLE
Chief Commercial Officer
Holding Value $1.92M 160,000 shares
Last Trade
Feb 17, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$12.7M 160,000 shares
$79.25
$12.01
Aeglea BioTherapeutics
Aeglea BioTherapeutics AGLE
Chief Commercial Officer
Holding Value $1.62M 135,000 shares
Last Trade
Feb 17, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$24.8M 135,000 shares
$183.75
$12.01
Aeglea BioTherapeutics
Aeglea BioTherapeutics AGLE
Chief Commercial Officer
Holding Value $300k 25,000 shares
Last Trade
Feb 14, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$5.09M 25,000 shares
$203.75
$12.01
Aeglea BioTherapeutics
Aeglea BioTherapeutics AGLE
Chief Commercial Officer
Holding Value $1.56M 130,000 shares
Last Trade
Oct 21, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$25.3M 130,000 shares
$194.75
$12.01

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up